Published in Gene Therapy Weekly, May 13th, 2004
"In response to DNA damage, the cell cycle checkpoint kinase 2 (CHEK2) may phosphorylate p53, Cdc25A and Cdc25C, and regulate BRCA1 function, leading to cell cycle arrest and DNA repair. The truncating germline mutation CHEK2*1100delC abrogates kinase activity and confers low-penetrance susceptibility to breast cancer," investigators in the Netherlands wrote.
Data show "CHEK2*1100delC in 0.5% of 190 esophageal squamous cell carcinomas and in 1.5% of 196 esophageal adenocarcinomas. In addition," the mutation was observed "in 3.0% of 99 Barrett's metaplasias and 1.5% of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.